Pharmacological and molecular insights into β-glucan-rich Saccharomyces cerevisiae var. boulardii: In vivo and in silico protection against arsenic-induced redox and hematologic imbalance
Investigational Medicinal Chemistry and Pharmacology · 31.01.2026 · 9 (1) · 1-10
DOI: 10.31183/imcp.2026.00126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational Medicinal Chemistry and Pharmacology, online erschienen am 28.02.2026. Verfasst von Moses Blessing Thomas und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Arsenic toxicity remains a major environmental and pharmacological concern in sub-Saharan Africa, with limited safe antidotes. Chronic exposure induces oxidative stress, hematologic dysfunction, and multi-organ injury through redox imbalance. Saccharomyces cerevisiae var. boulardii (SCb), a β-glucan-rich probiotic yeast, possesses antioxidant and immunomodulatory properties that may mitigate arsenic toxicity. This study combined in vivo and in silico approaches to elucidate the protective mechanisms of SCb against sodium arsenate-induced oxidative and hematologic alterations.
Methods
Thirty male Wistar rats were randomized into five groups (n = 6): control, arsenic only (100 mg/L), arsenic + SCb (500 mg/kg), arsenic + sodium thiosulfate (25 mg/kg), and SCb only. Treatments were administered orally for 28 days. Oxidative stress markers (malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT)) and hematologic indices (hemoglobin (Hb), Red blood cell (RBC), packed cell volume (PCV)) were evaluated. Major SCb bioactive compounds were docked against antioxidant enzymes (superoxide dismutase (SOD) and glutathione peroxidase (GPx)) using AutoDock Vina, while pharmacokinetic and drug-likeness properties were assessed using SwissADME.
Results
SCb exhibited no acute toxicity up to 6500 mg/kg. Arsenic significantly increased MDA and reduced CAT, SOD, PCV, and Hb (all p < 0.05). SCb co-treatment significantly improved CAT, SOD, PCV, and Hb when compared with arsenic alone (p < 0.05). Docking revealed strong binding affinities of 2,4-bis(1,1-dimethylethyl)-phenol and vanillic acid (–5.0 and –5.3 kcal/mol) with SOD and GPx, comparable to ascorbic acid. ADMET profiling demonstrated favorable pharmacokinetic properties. Conclusion: β-glucan-rich SCb confers significant protection against arsenic-induced oxidative and hematologic toxicity via antioxidant enzyme modulation and stable ligand–protein interactions.
Zitieren
APA
Thomas, M. B., Kum, M. J. T., Innocent, O., Vincent, O., Amaechi, O., Francis, U., Linus, A., Emmanuel, U., Ngozi, A., Samson, O., Remiguis, O., Mmesoma, I., & Joshua, P. E. (2026). Pharmacological and molecular insights into β-glucan-rich Saccharomyces cerevisiae var. boulardii: In vivo and in silico protection against arsenic-induced redox and hematologic imbalance. Investigational Medicinal Chemistry and Pharmacology, 9(1), 1-10. https://doi.org/10.31183/imcp.2026.00126
Vancouver
Thomas MB, Kum MJT, Innocent O, Vincent O, Amaechi O, Francis U, et al. Pharmacological and molecular insights into β-glucan-rich Saccharomyces cerevisiae var. boulardii: In vivo and in silico protection against arsenic-induced redox and hematologic imbalance. Investigational Medicinal Chemistry and Pharmacology. 2026;9(1):1-10. doi:10.31183/imcp.2026.00126
BibTeX
@article{Thomas2026,
author = {Thomas, Moses Blessing and Kum, Muankang Junior Tegha and Innocent, Orhonigbe and Vincent, Ozougwu and Amaechi, Ogara and Francis, Ugwuene and Linus, Agwu and Emmanuel, Uhuo and Ngozi, Achi and Samson, Onoyima and Remiguis, Onoja and Mmesoma, Ike and Joshua, Parker Elijah},
title = {Pharmacological and molecular insights into β-glucan-rich Saccharomyces cerevisiae var. boulardii: In vivo and in silico protection against arsenic-induced redox and hematologic imbalance},
journal = {Investigational Medicinal Chemistry and Pharmacology},
year = {2026},
volume = {9},
number = {1},
pages = {1--10},
doi = {10.31183/imcp.2026.00126}
}
EUVIMED